Literature DB >> 12680538

Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India.

B V Babu1, K Satyanarayana.   

Abstract

The paper attempts to report the factors responsible for the coverage and compliance of mass diethylcarbamazine citrate (DEC) administration, during the programme to eliminate lymphatic filariasis in the East Godavari District of Andhra Pradesh, India. The evaluation survey indicates that single dose DEC was received by 77% and taken by 64% of eligible people. Reasons for non-reception and non-consumption of the drug at household level were identified. The factors that influenced the coverage and compliance of treatment are broadly categorized as health services related, community related and drug related factors. The study identified some key factors to be followed for the success of the programme.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12680538     DOI: 10.1177/004947550303300208

Source DB:  PubMed          Journal:  Trop Doct        ISSN: 0049-4755            Impact factor:   0.731


  18 in total

1.  Elimination of lymphatic filariasis: mass drug administration in endemic areas of (bidar district) karnataka-2008.

Authors:  Ts Ranganath; N Ramakrishna Reddy
Journal:  Indian J Community Med       Date:  2012-10

2.  Defining optimal implementation packages for delivering community-wide mass drug administration for soil-transmitted helminths with high coverage.

Authors:  Marie-Claire Gwayi-Chore; Kumudha Aruldas; Euripide Avokpaho; Chawanangwa Maherebe Chirambo; Saravanakumar Puthupalayam Kaliappan; Parfait Houngbégnon; Comlanvi Innocent Togbevi; Félicien Chabi; Providence Nindi; James Simwanza; Jabaselvi Johnson; Edward J Miech; Khumbo Kalua; Moudachirou Ibikounlé; Sitara S R Ajjampur; Bryan J Weiner; Judd L Walson; Arianna Rubin Means
Journal:  BMC Health Serv Res       Date:  2022-06-18       Impact factor: 2.908

Review 3.  Community views on mass drug administration for filariasis: a qualitative evidence synthesis.

Authors:  Melissa Taylor; Rebecca Thomas; Sandy Oliver; Paul Garner
Journal:  Cochrane Database Syst Rev       Date:  2022-02-17

4.  Increasing compliance with mass drug administration programs for lymphatic filariasis in India through education and lymphedema management programs.

Authors:  Paul T Cantey; Jonathan Rout; Grace Rao; John Williamson; LeAnne M Fox
Journal:  PLoS Negl Trop Dis       Date:  2010-06-29

Review 5.  Understanding the community impact of lymphatic filariasis: a review of the sociocultural literature.

Authors:  Shona Wynd; Wayne D Melrose; David N Durrheim; Jaime Carron; Margaret Gyapong
Journal:  Bull World Health Organ       Date:  2007-06       Impact factor: 9.408

6.  Is the coverage of mass-drug-administration adequate for elimination of Bancroftian filariasis? An experience from West Bengal, India.

Authors:  Dibakar Haldar; Debkumar Ghosh; Dhruba Mandal; Abhik Sinha; Gautam Narayan Sarkar; Sucharita Sarkar
Journal:  Trop Parasitol       Date:  2015 Jan-Jun

7.  Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease.

Authors:  K D Ramaiah; Eric A Ottesen
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

8.  The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya.

Authors:  Doris W Njomo; Mary Amuyunzu-Nyamongo; Japheth K Magambo; Sammy M Njenga
Journal:  PLoS One       Date:  2012-11-19       Impact factor: 3.240

9.  An evaluation of mass drug administration compliance against filariasis of tikamgarh district of madhya pradesh-a household-based community study.

Authors:  Sandeep Singh; Meena Patel; Sugriv Singh Kushwah
Journal:  J Family Med Prim Care       Date:  2013-04

Review 10.  A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis.

Authors:  Alison Krentel; Peter U Fischer; Gary J Weil
Journal:  PLoS Negl Trop Dis       Date:  2013-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.